Advanced Biotherapy, Battelle in deal for anthrax treatment

By Elaine Rigoli

Tampa, Fla., March 22 - Advanced Biotherapy, Inc. announced Wednesday that it has entered into an initial memorandum of understanding (MOU) with Battelle for the development and use of monoclonal antibodies to treat humans and animals exposed to anthrax and plague as well as autoimmune diseases.

"Given the continued global threat of bioterrorism, the purpose of this initial MOU is to establish the basis for a cooperative institutional relationship between the company and Battelle to jointly participate in the 'Initiatives for Proliferation Prevention' projects of the U.S. Department of Energy, specifically regarding the development of anti-cytokine therapy as a treatment for anthrax and plague affecting humans and animals," Edmond Buccellato, chief executive officer of Advanced Biotherapy, said in a company statement.

Based in Los Angeles with laboratories in Columbia, Md., Advanced Biotherapy develops antibody and other anticytokine therapies for treating autoimmune diseases.

Columbus, Ohio-based Battelle develops and commercializes technology and manages laboratories for customers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.